- Sage Therapeutics Announces Phase 2 SURVEYOR Study Reinforces Cognitive Impact of Huntington’s Disease
- Sage Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- Sage Therapeutics to Participate in Upcoming May Investor Conferences
- Sage Therapeutics Announces First Quarter 2024 Financial Results and Highlights Pipeline and Business Progress
- Sage Therapeutics Announces Topline Results from Phase 2 PRECEDENT Study of Dalzanemdor (SAGE-718) in the Treatment of Mild Cognitive Impairment in Parkinson’s Disease
- Sage Therapeutics to Report First Quarter 2024 Financial Results on Thursday, April 25, 2024
More ▼
Key statistics
On Friday, SAGE Therapeutics Inc (SAGE:NMQ) closed at 10.78, 10.45% above the 52 week low of 9.76 set on Jun 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 10.57 |
---|---|
High | 10.99 |
Low | 10.30 |
Bid | 10.20 |
Offer | 12.00 |
Previous close | 10.62 |
Average volume | 1.36m |
---|---|
Shares outstanding | 60.18m |
Free float | 53.00m |
P/E (TTM) | -- |
Market cap | 648.76m USD |
EPS (TTM) | -8.40 USD |
Data delayed at least 15 minutes, as of Jul 05 2024 21:00 BST.
More ▼